Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avanos MedicalAVNS +0.04%62 Forward PE Ratio is 24.94 as of Jul. 17, 2026. GuruFocus rates AVNS with a GF Score™ of 62/100 and a GF Value™ of $19.38 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 392 Medical Devices & Instruments companies, Avanos Medical ranks worse than 63.78% on this metric.
Avanos Medical (NYSE:AVNS) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Avanos Medical Forward PE Ratio Related Terms
Avanos Medical Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Avanos Medical's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avanos Medical Forward PE Ratio Chart
Avanos Medical Annual Data
Trend
2015-12
2016-12
2017-12
2024-12
2025-12
Forward PE Ratio
17.12
20.00
22.32
9.36
12.01
Avanos Medical Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-06
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
17.12
18.42
21.41
20.75
20.00
20.58
21.83
21.74
22.32
31.85
9.36
12.40
14.36
13.03
12.01
13.51
AVNS vs LMRI, AORT, IRMD: Forward PE Ratio Comparison
For the Medical Devices subindustry, Avanos Medical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avanos Medical Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avanos Medical's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Avanos Medical's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Avanos Medical (AVNS) has a Forward PE Ratio of 24.94 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Avanos Medical and its competitors. According to the industry distribution chart, Avanos Medical ranks #250 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 63.8%.
Is Avanos Medical's Forward PE Ratio too high?
Avanos Medical's current Forward PE Ratio is 24.94. The Medical Devices & Instruments industry median Forward PE Ratio is 19.19. Avanos Medical's value of 24.94 is 30% above this industry median. Based on the distribution chart, Avanos Medical ranks #250 out of 392 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Avanos Medical has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avanos Medical's Forward PE Ratio compare to LMRI and AORT?
According to the Medical Devices & Instruments industry distribution chart, Avanos Medical ranks #250 out of 392 companies for Forward PE Ratio. This places Avanos Medical in the lower half of its industry. The industry median Forward PE Ratio is 19.19. Avanos Medical's value of 24.94 is 30% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.19, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avanos Medical's current Forward PE Ratio of 24.94 is 30% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Avanos Medical and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avanos Medical's current Forward PE Ratio is 24.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avanos Medical stock overvalued right now?
Based on GuruFocus' analysis, Avanos Medical (AVNS) is currently considered Modestly Overvalued. The stock's GF Value™ is $19.38, compared to a current price of $24.97 — trading 28.8% above its estimated fair value. The current Forward PE Ratio is 24.94 and 30% above the Medical Devices & Instruments industry median of 19.19. Avanos Medical's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Avanos Medical (AVNS), the current Forward PE Ratio is 24.94 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avanos Medical (AVNS) Overvalued in 2026?
Based on GuruFocus' analysis, Avanos Medical stock appears to be overvalued.
The current stock price of $24.97 is trading 28.8% above its estimated GF Value™ of $19.38.
GuruFocus considers Avanos Medical to be Modestly Overvalued.
Key valuation signals for AVNS:
Forward PE Ratio: 24.94
GF Value™: $19.38 vs. price of $24.97 (28.8% above fair value)
Industry Position: 30% above the Medical Devices & Instruments median (#250 of 392)
No single metric tells the full story. See the AVNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
62GF Score
Get the complete analysis for AVNS
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVNS has been successfully added to your 
